IRBM’s ADVENT GMP facility was recently mentioned in a Sunday Telegraph article covering the race to find a vaccine for COVID 19. The article talks about our collaboration with the Jenner Institute, Oxford University, who will produce the adenovirus-based  vaccine “seed stock” and ADVENT who will develop the GMP manufacturing process and manufacture 1,000 doses for the first clinical trials to take place at the end of the summer. ADVENT is currently focused on delivering a fast and efficient manufacturing process without compromising on quality. Unlike some of the other technologies being developed in the race for vaccine, adenovirus-based vaccines already have a precedent in clinic and ADVENT has a track record of successfully producing adenovirus vaccines for many infectious diseases such as Ebola and HIV.